Here are the 424B prospectus supplements from CG Oncology, Inc. (CGON) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CGON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGON filings page.
CG Oncology is amending its existing at-the-market common stock program with Jefferies to increase the aggregate offering capacity by an additional $500.0 million, bringing the total potential offering size to $1,050.0 million of common stock under its Form S-3ASR shelf. The company has already sold 10,800,525 shares for gross proceeds of approximately $550.0 million under the sales agreement.
Sales may be made from time to time as an “at the market offering” through Jefferies, which will earn up to 3.0% of gross proceeds. An illustrative scenario assumes selling 6,904,170 shares at $72.42 per share, implying immediate dilution of $55.92 per share to new investors versus an as adjusted net tangible book value of $16.50 per share. Net tangible book value as of March 31 2026 was $1,080.9 million, or $12.28 per share.
CG Oncology is updating its at-the-market equity program so it may sell up to $550.0 million of common stock through Jefferies under an existing sales agreement. The company has already sold 5,861,984 shares for gross proceeds of $250.0 million and is increasing the capacity by an additional $300.0 million. At a recent share price of $53.72, the amendment illustrates sales of 10,238,273 shares to raise about $550.0 million, which would raise net tangible book value per share from $8.60 to $13.62 as of September 30, 2025. New investors buying at that assumed price would face immediate dilution of $40.10 per share, and future option exercises or additional equity financings could further dilute existing holders.